synaptic plasticity is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-04-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
| Property | Value | Notes |
|---|---|---|
| Chemical name | N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Common full name in research literature. |
| Class | Synthetic peptide | Modified angiotensin IV analog. |
| Related compound | Angiotensin IV | Parent peptide fragment. |
| Proposed target | HGF/c-Met pathway | Described as an HGF mimetic; not fully confirmed. |
| Development status | Preclinical research | No widely approved clinical use. |
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
==== UCH37 ==== UCH37 is a Ubiquitin C-terminal hydrolase that activated upon binding the 26S proteasome through the ubiquitin receptor Rpn13. UCH37 is activated upon binding the proteasome through the C-terminal DEUBAD (DUB adaptor) domain that binds Rpn2.
element A species of atoms having the same number of protons in their atomic nuclei and hence the same atomic number. Chemical elements constitute all of the ordinary matter in the universe; 118 elements have been identified and are organized by their various chemical properties in the periodic table of the elements.
Cave paintings have been interpreted in a number of ways by modern archaeologists. The earliest explanation, by the prehistorian Abbe Breuil, interpreted the paintings as a form of magic designed to ensure a successful hunt. However, this hypothesis fails to explain the existence of animals such as saber-toothed cats and lions, which were not hunted for food, and the existence of half-human, half-animal beings in cave paintings. The anthropologist David Lewis-Williams has suggested that Paleolithic cave paintings were indications of shamanistic practices, because the paintings of half-human, half-animal figures and the remoteness of the caves are reminiscent of modern hunter-gatherer shamanistic practices. Symbol-like images are more common in Paleolithic cave paintings than are depictions of animals or humans, and unique symbolic patterns might have been trademarks that represent different Upper Paleolithic ethnic groups. Venus figurines have evoked similar controversy. Archaeologists and anthropologists have described the figurines as representations of goddesses, pornographic imagery, apotropaic amulets used for sympathetic magic, and even as self-portraits of women themselves. R. Dale Guthrie has studied not only the most artistic and publicized paintings, but also a variety of lower-quality art and figurines, and he identifies a wide range of skill and ages among the artists.
==== Jobs ==== Since the invention of the wheel, technologies have helped increase humans' economic output. Past automation has both substituted and complemented labor; machines replaced humans at some lower-paying jobs (for example, in agriculture), but this was compensated by the creation of new, higher-paying jobs. Studies have found that computers did not create significant net technological unemployment. Due to artificial intelligence being far more capable than computers, and still being in its infancy, it is not known whether it will follow the same trend; the question has been debated at length among economists and policymakers. A 2017 survey found no clear consensus among economists on whether AI would increase long-term unemployment. According to the World Economic Forum's "The Future of Jobs Report 2020", AI is predicted to replace 85 million jobs worldwide and create 97 million new jobs by 2025. From 1990 to 2007, a study in the U.S. by MIT economist Daron Acemoglu showed that an addition of one robot for every 1,000 workers decreased the employment-to-population ratio by 0.2%, or about 3.3 workers, and lowered wages by 0.42%. Concerns about technology replacing human labor, however, are long-lasting. As U.S. President Lyndon Johnson said in 1964 upon signing the National Commission on Technology, Automation, and Economic Progress bill, "Technology is creating both new opportunities and new obligations for us, opportunity for greater productivity and progress; obligation to be sure that no workingman, no family must pay an unjust price for progress."
Sources: en.wikipedia.org
=== Phase 2 === Aildenafil (methisosildenafil) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [10] AN-788 (IP-2018; IP2018; NSD788; NSD-788) – serotonin–dopamine reuptake inhibitor (SDRI) – erectile dysfunction [11] Apomorphine intranasal (AL-101; intranasal apomorphine) – non-selective dopamine receptor agonist, other actions – erectile dysfunction, female sexual dysfunction [12] Autologous mesenchymal stem cell therapy (autologous bone marrow-derived mesenchymal stem cell therapy; Cellgram; Cellgram-ED; Cellgram-LC; Cerecellgram-spine; Hearticellgram-AMI; Immunocellgram; Impocellgram; Livercellgram; Lungcellgram; MSC-1; MSC-2) – cell replacement – erectile dysfunction [13] Botulinum toxin A (AboBoNT-A; AbobotulinumtoxinA; Alluzience; Azzalure; BoNT-A; BTX-A-HAC; BTX-A-HAC NG; Clostridium botulinum toxin type A haemagglutinin complex; Dysport; Dysport NG; Dysport RU; Dysport Solution; Dysport Next Generation; Reloxin) – acetylcholine release inhibitor and neuromuscular blocking agent – vulvodynia [14] Bupropion/trazodone (Lorexys; Orexa; S1P-104; S1P-205; SIP-104; trazodone/bupropion) – combination of bupropion (norepinephrine–dopamine reuptake inhibitor (NDRI), other actions) and trazodone (serotonin antagonist and reuptake inhibitor (SARI), various actions) – erectile dysfunction, female sexual dysfunction, male sexual dysfunction [15] Buspirone/testosterone (Lybridos; testosterone/buspirone) – combination of buspirone (serotonin 5-HT1A receptor agonist, other actions) and testosterone (androgen) – female sexual dysfunction [16] BZ-371A (PnPP-19) – nitric oxide stimulant – erectile dysfunction, female sexual dysfunction [17] Cligosiban (IX-01; PF-3274167) – oxytocin receptor antagonist – premature ejaculation [18] Estetrol (Donesta; E4) – estrogen (estrogen receptor agonist) – atrophic vaginitis, female sexual dysfunction [19] Estriol vaginal ring (VR-102; VR102; long-acting estriol vaginal ring) – estrogen (estrogen receptor agonist) – atrophic vaginitis [20] Fadanafil (XZP-5849) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [21] FKW-00GA (FKW00GA; TGW-00AA; TGW00AA; TGWOOAA; TGW-OOAA) – serotonin 5-HT1A receptor agonist, serotonin 5-HT2A receptor antagonist – sexual function disorders [22] Onabotulinum toxin A (BoNTA; Botox; botulinum toxin A injectable; GSK-1358820; GSK1358820; OnabotA X; OnabotulinumtoxinA X; Vistabel; Vistabex) – acetylcholine release inhibitor and neuromuscular blocking agent – premature ejaculation [23] OPK-88004 (LY-2452473; TT701) – selective androgen receptor modulator (SARM) – erectile dysfunction [24] Pudafensine (IP2015; IP-2015) – serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) – erectile dysfunction, vulvodynia, female sexual dysfunction [25] Sildenafil/testosterone (Lybrido; testosterone/sildenafil) – combination of sildenafil (phosphodiesterase PDE5 inhibitor) and testosterone (androgen) – female sexual dysfunction [26] Sildenafil topical – phosphodiesterase PDE5 inhibitor – female sexual dysfunction [27] Testosterone intranasal (low-dose) (MPP-14; Noseafix; TBS-2; Tefina) – androgen (androgen receptor agonist) – anorgasmia, decreased libido [28] TGFK-09SD (TGFK09SD) – serotonin 5-HT1A receptor agonist – female sexual dysfunction [29] Volufralin (LIB-01; LIB01; DIC-2024; DIC2024; Libiguin) – indirect melanocortin MC4 receptor potentiator – erectile dysfunction, premature ejaculation [30]
CLASP is an international non-profit organization specializing in the energy efficiency of appliances, equipment, and lighting. Founded in 1999, CLASP has worked in over 90 countries, and is headquartered in Washington, DC with teams and offices in Brazil, Europe, India, Indonesia, Kenya, and the United Kingdom.
Rotheca myricoides or Butterfly Clerodendrum, Butterfly Bush, and (butterfly bush – also a name for Buddleja species) is a species of flowering plant in the family Lamiaceae. It is native to tropical eastern Africa and widely cultivated elsewhere. In cultivation, it is frequently known by one of its synonyms, such as Clerodendrum myricoides. The cultivar 'Ugandense' is an untidy evergreen shrub growing to 4 m (13 ft) tall and 2.5 m (8.2 ft) broad, with oval leaves and masses of pale-violet blue butterfly-like flowers in summer and autumn. Each flower has a darker blue lower petal. With a minimum temperature of 10 °C (50 °F), this plant can only be grown under glass in temperate zones. The altitude range for this species is 900–1680 m. The plant has won the Royal Horticultural Society's Award of Garden Merit.
This procedure can induce ovulation, typically leads to a single pregnancy, but other risks may be higher compared to medication. The procedure might lead to lower chance of live births compared to medication alone. Ovarian wedge resection is no longer used as much due to complications such as adhesions and the presence of frequently effective medications. As a final treatment option, in vitro fertilisation (IVF) can be considered. IVF does increase the risk of ovarian hyperstimulation syndrome. Using a 'freeze all' strategy makes it easier to transfer a single embryo and provides time for the ovaries to recover from hyperstimulation. A less effective alternative, but with much lower risks of ovarian hyperstimulation syndrome, is in vitro maturation instead of full IVF. This option avoids high-dose gonadotropin therapy.
A drop in progesterone levels is possibly one step in the onset of labor. In addition, progesterone inhibits lactation during pregnancy. The fall in progesterone levels following delivery is one of the triggers for milk production. The fetus metabolizes placental progesterone in the production of adrenal steroids.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.
No, dihexa is a synthetic compound derived from the structure of angiotensin IV. Angiotensin IV occurs naturally, but dihexa has modifications that change its properties. It is not a standard dietary component.
The main hypothesis is that dihexa interacts with the hepatocyte growth factor system, possibly through c-Met signaling. This interaction may influence synaptogenesis and neuronal plasticity. The exact molecular target remains an active area of study.
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.